Evidence map›Paper›PMID 36629439›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Design, synthesis, molecular modelling and antitumor evaluation of

Ahmed I Khodair, Fatimah M Alzahrani, Mohamed K Awad, Siham A Al-Issa, Ghaferah H Al-Hazmi, Mohamed S Nafie

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Synthesis,Journal of enzyme inhibition and medicinal chemistry · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ahmed I KhodairChemistry Department, Faculty of Science, Kafrelsheikh University, Kafrelsheikh, Egypt.ORCID 0000-0001-6674-4561
Fatimah M AlzahraniDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0000-0003-3183-2240
Mohamed K AwadTheoretical Applied Chemistry Unit (TACU), Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.ORCID 0000-0002-2649-9327
Siham A Al-IssaDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0000-0002-2919-0819
Ghaferah H Al-HazmiDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Mohamed S NafieChemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.ORCID 0000-0003-4454-6390
Princess Nourah bint Abdulrahman University · SAKafrelsheikh University · EGSuez Canal University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, 5-arylidene rhodanine derivatives

Indexed as

Antineoplastic AgentsRhodanineApoptosisCell ProliferationDNADNA Topoisomerases, Type IIDrug Screening Assays, AntitumorMolecular StructureStructure-Activity RelationshipTopoisomerase II InhibitorsAntineoplastic AgentsDNADNA Topoisomerases, Type IIRhodanineTopoisomerase II Inhibitorsantitumor activityapoptosisDFT calculationsmolecular modellingThiazolidinones

Identifiers

PMID36629439
PMCPMC9848385
OpenAlexW4315620548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.